

Reply all | Delete | Junk | ...

www.journalonweb.com/journal/showmail.aspx?ID=0F30AD7DAB0A341C573D750DCC3A96C44AA67AFD00C03D01300D2C331234FA23D

Apps | My Evaluations Logo | Bookmarks | Imported From IE | American Board of In | ACGME Home | CMEF Internal Medic

Journal On Web  
Journal of Cancer Research and Therapeutics

**Email**

Showing mail for : aarthi.rajkumar@aultman.com

**Date** Sunday, February 25, 2018 6:00:43 PM GMT

**Subject** Article provisionally accepted.

**Message** Dear Dr. Rajkumar,

NOTE: This e-mail is sent to you as one of the contributing authors. If you are not corresponding author, please co-ordinate with the author designated by your group as the corresponding author for this manuscript

Status of the manuscript titled "Yet another utility for Isocitrate dehydrogenase 1 (IDH1): Can it serve as an immunomarker to assess tumor margins in gliomas?" submitted by Dr. Shalinee Rao has been changed and a copy of the mail is as;

Dear Dr. Rao,

We are pleased to inform that your manuscript "Yet another utility for Isocitrate dehydrogenase 1 (IDH1): Can it serve as an immunomarker to assess tumor margins in gliomas?" is provisionally accepted. You would receive an edited version of article in about 2-3 weeks from now for a final check and correction.

We thank you for submitting your valuable research work to Journal of Cancer Research and Therapeutics.

With warm personal regards,

Yours sincerely,

Kishore Singh

Journal of Cancer Research and Therapeutics